Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.10
Bid: 9.70
Ask: 10.50
Change: 0.00 (0.00%)
Spread: 0.80 (8.247%)
Open: 10.10
High: 10.10
Low: 10.10
Prev. Close: 10.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Scancell trial progresses; OptiBiotix inks new deal

Tue, 28th Nov 2023 14:57

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says two more patients have responded to its Scope study, which brings the number of responders to 11 out of 13 patients. As a result, the objective response rate has increased to 85%. Notes one patient has achieved a complete response following treatment. The study has transitioned into the second stage, and Scancell plans to recruit a further 27 patients, with the aim to achieve at least 18 further responses. The trial investigates Scancell's SCIB1 vaccination combined with checkpoint inhibitors in advanced melanoma. Scancell reported in mid-September that SCIB1 combined with checkpoint inhibitors showed an 82% objective response rate. Chief Executive Officer Lindy Durrant says: "The Scope study continues to yield excellent results with two more responders and one of the previous patients now achieving a complete response." Durrant says Scancell now expects the iSCIB1+ cohort to start in the first quarter of 2024."

----------

EnSilica PLC - Abingdon, Oxfordshire-based semiconductor designer and supplier - Says performance in the first half of the financial year ending May 31, has been "resilient", buoyed by continued business momentum and "significant" contracts with "key customers". Remains confident in near-to-medium term prospects. Expects to trade in line with market expectations for financial 2024. EnSilica says analyst consensus currently forecast revenue of GBP22.9 million and earnings before interest, tax, depreciation and amortisation of GBP2.5 million.

----------

Orosur Mining Inc - South America-focused minerals explorer and developer - Says Lithium West joint venture has obtained results from its mapping and sampling programme, noting that "abundant" pegmatites are evident, with lithium superoxide results in excess of 2%. Says two additional licences have been confirmed, with its land position in the key lithium districts expanded to 533 square kilometres. CEO Brad George says: "These outstanding results from our first field program in Nigeria are exciting but not surprising. We pegged these licences with a very clear understanding of the geological processes in play, and so we expected to find lithium. To then confirm this confidence and to find so many lithium bearing pegmatites, some extremely thick, is very positive and bodes well for work on the next 5 licences that is underway now."

----------

Zenith Energy Ltd - Africa and Italy-focused oil and gas company - Signs memorandum of understanding with Nile Services & Logistics Co Ltd to jointly pursue business opportunities involving the construction of fuel products storage tanks, pipelines, and crude oil storage tanks in South Sudan. Zenith will provide technical, financial and managerial expertise in the construction of the tanks, while Nile Services will facilitate business opportunities. Zenith CEO Andrea Cattaneo says: "We are very pleased to have now signed an MoU with Nile SLC, a subsidiary of the national oil company of South Sudan, and we look forward with enthusiasm to jointly exploring opportunities in the midstream domain and beyond, specifically with regards to petroleum product trading activities." Also confirms that it is currently in the advanced phase of negotiating the potential acquisition of oil exploration and development licences in South Sudan.

----------

OptiBiotix Health PLC - York, England-based life sciences company - Inks deal with Ravenswood Ingredients Pty Ltd for the distribution of SlimBiome in Australia and New Zealand. "Ravenswood brings access to the food and beverage markets and will complement existing partner capabilities which are largely focused on the meal replacement market to broaden OptiBiotix's impact in Australia and New Zealand. This is part of a strategy of building partnerships to support expansion of OptiBiotix's geographical footprint with companies who bring national and international capability for highly differentiated value-added ingredients in high growth markets around the world," it says. CEO Stephen O'Hara comments: "We are pleased to announce this agreement with Ravenswood who bring specialised food ingredient expertise as part of the Brenntag group, a global market leader in chemicals and ingredients distribution. This agreement is another example of OptiBiotix working with large partners and extends access to the food and beverage markets within Australia and New Zealand with a company which is part of a group which is a global leader in the ingredients market."

----------

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
20 Jul 2016 12:35

Scancell granted product licence extension from Ichor Medical Systems

(ShareCast News) - Scancell, the developer of immunotherapies for cancer treatments, was granted a product licence option extension from Ichor Medical Systems. The extension is to licence the commercial use of Ichor's TriGrid electroporation delivery system with SCIB1, Scancell's ImmunoBody vaccine,

Read more
20 Jul 2016 08:30

Scancell Licence To Use TriGrid Technology Extended To 2018 (ALLISS)

Read more
13 Jul 2016 09:19

Scancell Says Review Supporting Potential Of Moditope Published

Read more
6 Jul 2016 08:28

Scancell Holdings SCIB1 Cancer Drug Shows "Compelling" Survival Data

Read more
17 Jun 2016 12:24

Scancell suspends dosing with current supplies of SCIB1 for melanoma

(ShareCast News) - Shares in drug developer Scancell Holdings plunged almost 17% after it suspending dosing with current clinical trial supplies of SCIB1 for melanoma with immediate effect. Patients would be notified as soon as possible. AIM-quoted Scancell said quality-control analysis showed the

Read more
17 Jun 2016 09:46

WINNERS & LOSERS SUMMARY: National Grid Hit By Break-Up Recommendation

Read more
17 Jun 2016 08:10

UPDATE 1-Scancell slumps as drug problem disrupts melanoma trial

(Adds latest shares, details) LONDON, June 17 (Reuters) - British drug developer Scancell has suspended dosing in a cancer clinical trial because of quality problems with an immunotherapy treatment, wiping more than a quarter off the value of its shares on Friday. The company said te

Read more
17 Jun 2016 07:46

BUZZ-Scancell: drug problem spurs worst day in 3 yrs

** Drug developer Scancell's shares down 27 pct, worst day in nearly three years, after suspends dosing in a cancer clinical trial because of quality problems with its immunotherapy treatment SCIB1 ** Co says current supplies of drug no longer meet original specification and are no longer s

Read more
17 Jun 2016 06:51

Drug problem forces Scancell to suspend cancer trial dosing

LONDON, June 17 (Reuters) - British drug developer Scancell said on Friday it was suspending dosing in a cancer clinical trial because of quality problems with its immunotherapy treatment SCIB1. The company said tests showed the product, which is being assessed for melanoma, was "no longer

Read more
17 Jun 2016 06:44

Scancell Holdings Suspends Dosing In SCIB1 Cancer Treatment Trials

Read more
2 Jun 2016 07:57

Scancell's ImmunoBody Platform Chosen For Preclinical Glioma Study

Read more
19 May 2016 05:55

CORRECT (18/05): Scancell Shuffles Board As New US Offices Open

Read more
18 May 2016 08:31

BROKER RATINGS SUMMARY: Goldman Upgrades Booker, Panmure Cuts Meggitt

Read more
18 May 2016 08:06

Scancell Shuffles Board As New US Offices Open, Plans For Oxford Base

Read more
4 Apr 2016 11:47

Scancell raises £6.2m in placing and open offer

(ShareCast News) - Scancell revealed the final results of its placing and open offer on Monday, with a few more subscriptions received since the firm's last update on 1 April. The AIM-traded company had announced on Friday that it had received subscriptions for 16,048,593 new ordinary shares of the

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.